Key Market Indicator:
In this news category you will find information from and about companies, organizations, institutions, products of all kinds and in a broad spectrum. To get a quick overview of current trends and developments, it's worth visiting daily.
NL0011832936
Wed, 06.12.2023
Cosmo Pharmaceuticals N.V.
Cosmo Pharmaceuticals N.V.
/ Key word(s): Bond
Cosmo confirms full redemption in cash of €175m Convertible Bonds
06.12.2023 / 06:00 GMT/BST
Dublin, Ireland – 06 December 2023: Cosmo Pharmaceuticals N.V. (SIX: COPN, XETRA: C43) (“Cosmo”) announced today that it has fully redeemed all of its EUR 175 million 2.5% Senior Un [ … ]
Tue, 10.10.2023
Cosmo Pharmaceuticals N.V.
Cosmo Pharmaceuticals N.V.
/ Key word(s): Regulatory Admission
Cosmo announces submission of Winlevi® to the European Medicines Agency (EMA)
10.10.2023 / 06:00 GMT/BST
Submission to EMA is supported and based on the efficacy and safety evidence gathered in two identical, randomized, placebo-controlled phase II [ … ]
Mon, 02.10.2023
Cosmo Pharmaceuticals N.V.
Cosmo Pharmaceuticals N.V.
/ Key word(s): Agreement
Cosmo and Hikma Sign License Agreement for Winlevi® in 17 Middle Eastern and North African Countries
02.10.2023 / 06:00 GMT/BST
Dublin, Ireland – 02 October 2023: Cosmo Pharmaceuticals N.V. (SIX: COPN, XETRA: C43) (“Cosmo”) and Hikma Pharmaceuticals PLC (LSE: [ … ]
Mon, 04.09.2023
Cosmo Pharmaceuticals N.V.
Cosmo Pharmaceuticals N.V.
/ Key word(s): Agreement
Cosmo and Adalvo sign License and Supply Agreement for Rifamycin SV MMX® 200mg in Europe, APAC, MENA and LATAM regions
04.09.2023 / 06:00 GMT/BST
Dublin, Ireland – 4 September 2023: Cosmo Pharmaceuticals N.V. (SIX: COPN, XETRA: C43) (“Cosmo”) and Adalvo Ltd [ … ]
Mon, 04.09.2023
Cosmo Pharmaceuticals N.V.
Cosmo Pharmaceuticals N.V.
/ Key word(s): Agreement
Termination of Agreement for Rifamycin SV MMX® with Dr. Falk Pharma
04.09.2023 / 05:45 GMT/BST
Dublin, Ireland – 4 September 2023: Cosmo Pharmaceuticals N.V. (SIX: COPN, XETRA: C43) (“Cosmo”) today announced the termination by mutual agreement of the license [ … ]
Wed, 05.07.2023
Cosmo Pharmaceuticals N.V.
Cosmo Pharmaceuticals N.V.
/ Key word(s): Half Year Results
Invitation to Cosmo’s Half-Year 2023 Webcast on 26 July 2023
05.07.2023 / 06:15 GMT/BST
Dublin, Ireland – 5 July 2023: Cosmo Pharmaceuticals N.V. (SIX: COPN, XETRA: C43) (“Cosmo”) announced today that it will publish its Half-Year 2023 results on Wed [ … ]
Wed, 05.07.2023
Cosmo Pharmaceuticals N.V.
Cosmo Pharmaceuticals N.V.
/ Key word(s): Half Year Results
Invitation to Cosmo’s Half-Year 2023 Webcast on 26 July 2023
05.07.2023 / 06:15 GMT/BST
Dublin, Ireland – 5 July 2023: Cosmo Pharmaceuticals N.V. (SIX: COPN, XETRA: C43) (“Cosmo”) announced today that it will publish its Half-Year 2023 results on Wed [ … ]
Thu, 29.06.2023
Cosmo Pharmaceuticals N.V.
Cosmo Pharmaceuticals N.V.
/ Key word(s): Study
Cosmo announces the beginning of the phase III trials in males for the treatment of androgenetic alopecia
29.06.2023 / 06:15 GMT/BST
Dublin, Ireland – June 29, 2023: Cosmo Pharmaceuticals N.V. (SIX: COPN, XETRA: C43) (“Cosmo”) today announced the beginning of th [ … ]
Thu, 29.06.2023
Cosmo Pharmaceuticals N.V.
Cosmo Pharmaceuticals N.V.
/ Key word(s): Study
Cosmo announces the beginning of the phase III trials in males for the treatment of androgenetic alopecia
29.06.2023 / 06:15 GMT/BST
Dublin, Ireland – June 29, 2023: Cosmo Pharmaceuticals N.V. (SIX: COPN, XETRA: C43) (“Cosmo”) today announced the beginning of th [ … ]
Wed, 28.06.2023
Cosmo Pharmaceuticals N.V.
Cosmo Pharmaceuticals N.V.
/ Key word(s): Product Launch
Cosmo announces Cortiment® approval in Japan
28.06.2023 / 06:15 GMT/BST
Dublin, Ireland – 28 June 2023: Cosmo Pharmaceuticals N.V. (SIX: COPN, XETRA: C43) (“Cosmo”) today announced that its partner Ferring Pharmaceuticals (“Ferring”) has received the ap [ … ]